| First Author | Augoff K | Year | 2015 |
| Journal | Cancer Lett | Volume | 358 |
| Issue | 1 | Pages | 1-7 |
| PubMed ID | 25528630 | Mgi Jnum | J:218832 |
| Mgi Id | MGI:5618565 | Doi | 10.1016/j.canlet.2014.12.035 |
| Citation | Augoff K, et al. (2015) Lactate dehydrogenase 5: an old friend and a new hope in the war on cancer. Cancer Lett 358(1):1-7 |
| abstractText | A hallmark of most cancer cells is an altered metabolism involving a shift to aerobic glycolysis with lactate production coupled with a higher uptake of glucose as the main source of energy. Lactate dehydrogenase 5 (LDH-5) catalyzes the reduction of pyruvate by NADH to form lactate, thus determining the availability of NAD(+) to maintain the continuity of glycolysis. It is therefore an important control point in the system of cellular energy release. Its upregulation is common in many malignant tumors. Inhibiting LDH-5 activity has an anti-proliferative effect on cancer cells. It may reverse their resistance to conventional chemo- and radiotherapy. Recent research has renewed interest in LDH-5 as an anticancer drug target. This review summarizes recent studies exploring the role of LDH-5 in cancer growth, its utility as a tumor marker, and developments made in identifying and designing anti-LDH-5 therapeutic agents. |
